LSBC Q4 Revenues Down Slightly; R&D Costs Up 87 Percent | GenomeWeb

NEW YORK, Feb 1 – Large Scale Biology's fourth quarter revenues decreased slightly from a year ago, the company reported Thursday. LSBC attributed the drop in revenue, from $5.9 to $5.7 million, primarily to decreased development funding from Dow Chemical and Dow AgroSciences.

Higher R&D costs in the fourth quarter of 2000 compounded the drop in contract funding from Dow, the company said. Compared to the year-ago fourth quarter, R&D expenditures were up 87 percent to $4.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.